Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 4/20 | 0.34 |
| ▸ | F11 | P03951 | 4/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 2/20 | 0.31 |
| ▸ | TPSB2 | P20231 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16410305 | 0.97 | AAK1 (0.35) | CFDF11KLKB1AAK1USP30 | |
| SCHEMBL17764449 | 0.89 | CFD (0.39) | CFDF11KLKB1PPARGTPSB2 | |
| SCHEMBL16396804 | 0.86 | CFD (0.40) | CFDF11KLKB1TPSB2 | |
| SCHEMBL16396642 | 0.83 | PTGER1 (0.36) | CFDF11KLKB1CACNA1BHPGD | |
| SCHEMBL16396865 | 0.83 | RIPK1 (0.36) | CFDF11KLKB1AAK1USP30 | |
| SCHEMBL16410393 | 0.82 | CFD (0.41) | CFDF11KLKB1AAK1TPSB2 | |
| SCHEMBL16396123 | 0.81 | AAK1 (0.40) | CFDF11KLKB1AAK1TPSB2 | |
| SCHEMBL16397485 | 0.80 | CFD (0.41) | CFDF11KLKB1AAK1TPSB2 | |
| SCHEMBL16396471 | 0.80 | AAK1 (0.37) | CFDF11KLKB1AAK1TPSB2 | |
| SCHEMBL16396785 | 0.80 | POLB (0.36) | CFDF11KLKB1TPSB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| WO-2015009977-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | CFD, CFH, CFB | CFD 1/4885F11 17/4885KLKB1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.